We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Cardiology

Journal Scan / Research · March 25, 2021

Effect of CYP2C19 Genotype on Ischemic Outcomes During Oral P2Y12 Inhibitor Therapy

JACC: Cardiovascular interventions


Additional Info

JACC: Cardiovascular interventions
Effect of CYP2C19 Genotype on Ischemic Outcomes During Oral P2Y12 Inhibitor Therapy: A Meta-Analysis
JACC Cardiovasc Interv 2021 Mar 10;[EPub Ahead of Print], NL Pereira, C Rihal, R Lennon, G Marcus, S Shrivastava, MR Bell, D So, N Geller, SG Goodman, A Hasan, A Lerman, Y Rosenberg, K Bailey, MH Murad, ME Farkouh

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading